Ebola -- DR Congo
- The Ethics Committee approved the use of 4 additional experimental therapeutic molecules, namely ZMapp, Remdesivir, Favipiravir, and Regn3450 - 3471 - 3479. Ebola Treatment Centers (ETC) treatment and care teams will be able to use these molecules for the treatment of patients infected with Ebola virus disease. The protocols for administering these molecules meet strict conditions related in particular to the condition of the patient, the ease of use of the treatment and the capacity of the
Read more about it at HealthMap Global Disease Alerts via http://healthmap.org/ln.php?5979052&promed&0
No comments:
Post a Comment